Drug Profile


Alternative Names: Glucosaminyl muramyl dipeptide; Glycopin; Licopid

Latest Information Update: 19 Mar 2003

Price : $50

At a glance

  • Originator Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
  • Developer Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry; ZAO Peptech; ZAO Peptek
  • Class Antineoplastics; Antipsoriatics; Antivirals; Dipeptides; Glycopeptides; Muramic acids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Herpesvirus infections; Lung disorders; Postoperative infections; Psoriasis; Respiratory tract disorders; Tuberculosis
  • No development reported Chemoprotection; Neutropenia; Pyoderma

Most Recent Events

  • 19 Mar 2003 No development reported - Phase-II for Pyoderma in Russia (IM)
  • 19 Mar 2003 No development reported - Preclinical for Chemoprotection in United Kingdom (PO)
  • 19 Mar 2003 No development reported - Phase-II for Chemoprotection in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top